Latest Articles
Association of Wearable Device-Measured Vigorous Intermittent Lifestyle Physical Activity with Mortality
This prospective cohort study analyzed data from 25,241 non-exercising adults (mean age 61.8 years) in the UK Biobank to assess the impact of vigorous intermittent lifestyle physical activity (VILPA) on mortality. VILPA, characterized by brief bouts (1–2 minutes) of vigorous activity during daily life, was measured using wearable accelerometers. Over
Can a bout of exercise harm the human heart?
This commentary discusses a study by Stewart et al. (2016) that examined the effects of acute endurance exercise on cardiac function in recreationally active men. Participants performed two cycling trials: 90 minutes at heavy intensity and 120 minutes at moderate intensity. Findings indicated transient reductions in left and right ventricular
Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine
This 2024 study evaluated the accuracy of a compact, disposable pressure monitoring device (Compass™) used during partial REBOA procedures in a swine model. Four Yorkshire pigs underwent induced hemorrhagic shock followed by REBOA with the Compass™ transducer. Mean arterial pressures recorded by the device were compared to standard arterial line
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
This 2022 extension of the STEP 1 trial assessed the effects of discontinuing semaglutide 2.4 mg weekly in adults with obesity. After 68 weeks of treatment, participants had lost an average of 17.3% of their body weight. One year post-withdrawal, they regained approximately two-thirds of this weight loss, resulting in
Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial
This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or
Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database
This 2025 study conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) to identify drugs associated with noninfectious myocarditis. Analyzing data from 2004 to 2024, the researchers found 10,763 reports of noninfectious myocarditis. The top five drugs with the highest reporting odds ratios (RORs) were phendimetrazine tartrate